CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tetra Bio Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tetra Bio Pharma Inc
2316 St-Joseph Blvd.
Phone: (343) 689-0714p:343 689-0714 ORLEANS, ON  K1C 1E8  Canada Ticker: TBPMQTBPMQ
Filed for Bankruptcy on 8/1/2023
On 8/1/2023, Tetra Bio-Pharma Inc. announced its decision to make a Voluntary Assignment into Bankruptcy under the Bankruptcy and Insolvency Act (Canada).
Houleroy S.A. has been appointed as the Trustee.
Business Summary
Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
8/31/202211/30/2021YesYes---

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board BrentNorton 64 9/14/2020 8/18/2020
Chief Executive Officer, Director, Chief Regulatory Officer GuyChamberland 10/1/2020 6/1/2016
Chief Financial Officer LeslieAuld 5/30/2022 5/30/2022
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Laboratoires Holizen Inc. 4500 Bd Kimber Saint-Hubert QC Canada

Business Names
Business Name
9048073 Canada Inc.
GrowPros Agro-Tek Inc.
GrowPros MMP Inc.
7 additional Business Names available in full report.

General Information
Number of Employees: 33 (As of 11/30/2021)
Outstanding Shares: 515,634,205 (As of 4/12/2023)
Stock Exchange: OTC
Fax Number: (343) 689-0716


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024